Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma.

Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM.

Breast Cancer Res. 2011 May 18;13(3):R51. doi: 10.1186/bcr2882.


Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.

Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, Harrison DJ.

J Vis Exp. 2011 Oct 25;(56):e3334. doi: 10.3791/3334.


Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Dec 1;25(34):5418-25.


Quantitative analysis of estrogen receptor heterogeneity in breast cancer.

Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL.

Lab Invest. 2007 Jul;87(7):662-9. Epub 2007 Mar 5.


Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL.

Breast Cancer Res. 2011 Nov 2;13(5):R85. doi: 10.1186/bcr2937.


Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?

Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schnitt SJ.

Mod Pathol. 1998 Mar;11(3):259-64.


Intratumor heterogeneity of biomarker expression in breast carcinomas.

Chhieng DC, Frost AR, Niwas S, Weiss H, Grizzle WE, Beeken S.

Biotech Histochem. 2004 Feb;79(1):25-36.


Mixture classification model based on clinical markers for breast cancer prognosis.

Zeng T, Liu J.

Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14.


Prognostic value of different factors in breast carcinoma.

Hlupić L, Jakić-Razumović J, Bozikov J, Corić M, Belev B, Vrbanec D.

Tumori. 2004 Jan-Feb;90(1):112-9.


Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction.

Baneshi MR, Warner P, Anderson N, Edwards J, Cooke TG, Bartlett JM.

Br J Cancer. 2010 May 11;102(10):1503-10. doi: 10.1038/sj.bjc.6605627.


Biomarkers characterization of circulating tumour cells in breast cancer patients.

Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, Macià M, Corominas JM, Delgado-Rodriguez M, Gonzalez L, Albanell J, Fernández M, Solé F, Lorente JA, Serrano MJ.

Breast Cancer Res. 2012 May 3;14(3):R71.


Cytologic evaluation of prognostic markers in breast carcinoma.

Jayaram G, Elsayed EM.

Acta Cytol. 2005 Nov-Dec;49(6):605-10.


Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.

Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ.

J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9.


Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

Breast Cancer Res. 2008;10(5):R86. doi: 10.1186/bcr2156. Epub 2008 Oct 16.


Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.

Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X.

BMC Cancer. 2008 Mar 28;8:83. doi: 10.1186/1471-2407-8-83.


Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.


Semi-quantitative RT-PCR assessment of molecular markers in breast large-core needle biopsies.

Pohlodek K, Galbavý S, Bartosová M, Mucha V, Holomán K, Pastorek J, Pastoreková S.

Neoplasma. 2004;51(6):415-21.


Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C.

Mol Cancer. 2006 Jun 19;5:24.

Items per page

Supplemental Content

Write to the Help Desk